Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. (SNPHY) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Santen Pharmaceutical Co., Ltd. (SNPHY), covering cash flow, earnings, and balance sheets.
Santen Pharmaceutical Co., Ltd. (SNPHY) Income Statement & Financial Overview
View the income breakdown for Santen Pharmaceutical Co., Ltd. SNPHY across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $77.23B | $76.37B | $71.63B | $74.77B |
| Cost of Revenue | $33.51B | $34.13B | $31.50B | $34.44B |
| Gross Profit | $43.72B | $42.23B | $40.13B | $40.33B |
| Gross Profit Ratio | $0.57 | $0.55 | $0.56 | $0.54 |
| R&D Expenses | $7.33B | $5.83B | $5.44B | $5.50B |
| SG&A Expenses | $23.27B | $22.49B | $20.84B | $21.38B |
| Operating Expenses | $30.59B | $30.45B | $28.05B | $29.61B |
| Total Costs & Expenses | $64.10B | $64.59B | $59.55B | $61.62B |
| Interest Income | $2.57B | $421.00M | $306.00M | $702.00M |
| Interest Expense | $1.40B | $273.00M | $636.00M | $407.00M |
| Depreciation & Amortization | $4.40B | $4.51B | $4.33B | $4.71B |
| EBITDA | $18.66B | $15.83B | $15.05B | $18.57B |
| EBITDA Ratio | $0.24 | $0.21 | $0.21 | $0.25 |
| Operating Income | $13.13B | $11.78B | $12.08B | $13.16B |
| Operating Income Ratio | $0.17 | $0.15 | $0.17 | $0.18 |
| Other Income/Expenses (Net) | -$270.00M | -$313.00M | -$1.69B | $294.00M |
| Income Before Tax | $12.86B | $11.47B | $10.39B | $13.45B |
| Income Before Tax Ratio | $0.17 | $0.15 | $0.15 | $0.18 |
| Income Tax Expense | $3.67B | $2.83B | $2.29B | $2.84B |
| Net Income | $8.78B | $8.69B | $8.14B | $10.63B |
| Net Income Ratio | $0.11 | $0.11 | $0.11 | $0.14 |
| EPS | $25.74 | $25.23 | $23.15 | $29.61 |
| Diluted EPS | $25.69 | $25.23 | $23.15 | $29.50 |
| Weighted Avg Shares Outstanding | $341.36M | $344.75M | $351.43M | $359.15M |
| Weighted Avg Shares Outstanding (Diluted) | $341.36M | $344.75M | $351.43M | $360.44M |
Over the last four quarters, Santen Pharmaceutical Co., Ltd.'s revenue moved from $74.77B in Q1 2024 to $77.23B in Q4 2024. Operating income in Q4 2024 was $13.13B, with a strong operating margin of 17%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Santen Pharmaceutical Co., Ltd. remained robust at $18.66B, reflecting operational efficiency. Net income rose to $8.78B, with an EPS of $25.74. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan